Fig. 4
From: A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
GSK461364 attenuated pulmonary fibrosis with acceptable mortality and weight loss. (A) C57BL/6 mice received bleomycin (3 mg/kg, intratracheal instillation) on day 0. GSK461364 (injected intraperitoneally at a dose of 5 mg/kg) or vehicle was administered twice a week. Analyses were performed on day 21. The change in the body weight of each group (B) and a Kaplan-Meier plot showing the survival in each group (C) (n = 3, control group; n = 16, bleomycin-alone group; n = 17, bleomycin + GSK461364 5 mg/kg group). (D) A histological examination was performed with hematoxylin and eosin staining. Scale bars, 1000 μm. (E) The fibrotic changes in the lungs were quantified with a numerical fibrotic score (Ashcroft score) histopathologically (n = 3, control group; n = 14, bleomycin-alone group; n = 13, bleomycin + GSK461364 5 mg/kg group). (F) The collagen content in the left-lung lobe was measured using a hydroxyproline colorimetric assay (n = 3, control group; n = 14, bleomycin-alone group; n = 13, bleomycin + GSK461364 5 mg/kg group). Data were analyzed using a one-way analysis of variance followed by Dunnett’s multiple comparison test and were displayed as the mean ± SD. For all graphs: * P = 0.01–0.05; ** P = 0.001–0.01; *** P < 0.0001. The P values of each experiment are shown above each figure